Get started

Pharmastocks

TEVA is recharging the battery waiting next earnings release ($TEVA) was accelerating the uptrend but since some days it has come back on its path inside a bullish flag. It is important to note that next week earnings will be released so high volatility should be expected. Masch is about to turn on bullish mode RSI is quite down and vortex is neutral. I might expect that some investors will get long before the earnings pushing the price up but it is just an hypothesis. So far we are still inside the range with lower and upper edges showed on the chart.
NYSE:TEVA
by TRADOMICS_
Alexion (AXLN): new entry longTime to raise up the head has come for ALexion pharmaceuticals. After some years in a trading range and a never ending downtrend since 2015 (black line) price has broken it up reaching recently 135.87 dollars. As showned in the graph we have an important technical signal which is the cross between MA 50 and MA 200. We have also the RSI confirming tghe momentum and an entry buy from vortex. Volume is neither low nor high but enough to confirm the uptrend, given trendlines and the mix of the other indicators. Price has borken the dynamic resistence at 128.41, the short term trading range YTD.
ALong
by TRADOMICS_
$ATNM Actinium; Breaking outGot a stock play here since the crypto market is balls deep in a downtrend -- for those who have only traded in crypto I recommend the Robinhood app for commission-free trades (link below). I've been using this app for a while and don't have any complaints other than the ridiculous "Pattern Day Trading" rule enforcement, but thats a topic for a rant on another medium. (Note: This law is imposed by the govt and has nothing to do with Robinhood) ATNM has a great setup and is obviously breaking towards new resistance points with very bullish signals on most indicators. Analyst Consensus 1YR Target is $4.00+, so this is a good buy even after some stair steps that I think we'll see this week & next. Will try to update as often as possible and add new details for fundamental analysis. GLTA Signup here and we both get a free share of stock! robinhood.com
AMEX:ATNMLong
by Occamstock
ATNX to retest Support high 17's to mid 18'sATNX may be a tad over extended for now and will likely retrace to it's 18.50 or high 17's support area. May look for a buy in here. ANTX recently named Timothy Cook as senior vice president of global commercial oncology. This is recent add to an all star team in the oncology pharma space. I see a bright future for this asset. ***Any information represented here is my opinion only and not intended to be used for financial gain. None of the information posted here is to be considered financial advice. Information posted here is strictly for entertainment purposes only. Please consult your financial professional before making any kind of investment. Investments can be very risky and any investor should educate themselves before investing by enlisting the help of a financial professional. Past results are not indicative of future results in any construable way.***
A
by algocowboy2030
SGYP Is Setting Up for A Big Move!SGYP seems to be setting up for a big big move. The Squeeze Momentum Indicator has been forming a triangle which is now about to close and the crosses in the indicator have been black for some time meaning that a release of the squeeze should be about to manifest. My guess is that spike will be to the upside, and it could go as high as 3.60$ (90%+ appreciation), which is the 0.382 retracement level of 17's highs and the 1.618 retracement level of this year's highs.
SLong
by ArthaVidya
1
Small Pharma Big Backers and Partners - LONG SNG (Synairgen)Prudent Drug Discovery Company Low market cap ( appox £13m at time of writing ). Issues shares very rarely ( last placing nearly four years ago ). Has material interest in its work from larger partners ( Pharmaxis ). Sold interest in LOXL2 programme for £5m to Pharmaxis in December. Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest across all fibrotic indications at circa 17% of all partnering proceeds. Potential of drug appears across multiple uses now ( not just lung-related ) and indications from Pharmaxis looking very good. Recent interviews from Pharmaxis management suggest a good chance of a deal with major pharma in H2. Low free float in the stock ( 60% in hands of major shareholders ). Major funds holding ( Woodford Investment Management and Lansdowne Partners ). High profile investors holding stakes ( Richard Griffiths and Leonard Licht ). These high profile investors have been raising, rather than reducing their stakes in the company, periodically. For a risky smallcap biotech stock it appears well placed to survive and thrive, regardless of the short term success of a sale/licencing deal of LOXL2 by Pharmaxis, making it considerably less risky than most biotech stocks in the long term. However, the indications and noises being made about LOXL2 by Pharmaxis are looking as positive as you could hope for, and backed up by them putting their money where their mouth is in the first place and increasing their stake for cash.
LSE:SNGLong
by richthenewbie
3
INSY Target $23 FDA Cannabidiol Fast trackFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes. “FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, a debilitating condition which currently does not have any approved products available,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “We plan to start the clinical development program for this promising therapy in late first quarter of 2018.” The most common known genetic cause of life-threatening obesity in children, Prader-Willi syndrome has a prevalence of approximately 1 in 15,000, according to the Prader-Willi Syndrome Association, occurring in males and females equally and in all races. “We are very encouraged by the FDA’s decision to put CBD for Prader-Willi on the Fast Track and believe it is good news for these young patients, their families and clinicians,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “This special regulatory designation represents a significant milestone in the company’s R&D program, which is focused on developing and delivering safe, effective and novel treatment options using cannabinoids and novel drug delivery technology for unmet medical needs.” About INSYS INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. Forward-Looking Statements This news release contains forward-looking statements including regarding (i) our belief that FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, (ii) our belief that Prader-Willi syndrome currently does not have any approved products available and that our proprietary CBD formulation has potential to be a viable treatment option and (iii) our plan to start the clinical development program for this promising therapy in late first quarter of 2018. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
ILong
by StockPicksNYC98
Finding the upcoming support zone and the right time to sell/buyAcadia Pharmaceuticals has shown a downward swing during the past 2 business days or so. Before that it was on a very big run, which on my opinion was due to the high demand and the low buy/sell price. It will soon find support around the 32.67 up to the 38 zone (see the purple channel) based on the past downswing which i just stated. In the very near future it will also go on an run as big as the last one or maybe a little slower, but it will fall out again. In my opinion it would be better to buy soon, sell some when it breaks the channel and then sell more when it reaches the climax of the channel.
NASDAQ:ACAD
by AlbanSako
LLY Eli Lilly: Where can we buy?This stock has been in a correction for about a year now and it looks like it is not done yet. Looking to the price history on the left we can see that we could soon hit strong support starting from $60.00 which is basically the top of a $48-60 price channel. So I would be looking to buy anywhere below $60 if we re-enter that channel (yellow box). I don't expect price to just move through this channel, just like we cannot just break through a herd of cows crossing the street while driving. In addition, if we copy the move from the swing highs to swing lows from 2015-2016 we can see that an equal move would end right around $60 as well, providing a further reason for entry.
NYSE:LLYLong
by PHL